Literature DB >> 33576042

Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico-pathologic correlation.

Cristina Moya-Martínez1, Juan Torre-Castro1, Mª Carmen Fariña-Sabarís1, Diana Santiago Sánchez-Mateos1, Itziar Eraña-Tomás2, Margarita Jo-Velasco2, Luis Requena1.   

Abstract

Targeted anticancer therapy is being used with greater frequency and dermatologic toxicities are among the most frequent adverse events of these drugs. However, histopathological features of these adverse events are not yet well characterized. We present two cases of clinically different cutaneous toxicities on two patients with hematologic neoplasia. They were treated with different drugs and in both cases medications shared inhibition of PI3K as mechanism of action. The skin biopsy specimen showed endothelial cell atypia with large nuclei and mitotic figures. To the best of our knowledge, no other cases with these striking histopathologic findings have been reported with PI3K inhibitors or other anticancer targeted therapy.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  PI3K inhibitors; cutaneous drug eruption; endothelial atypia

Year:  2021        PMID: 33576042     DOI: 10.1111/cup.13981

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  1 in total

1.  Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study.

Authors:  Ruofei Du; Huashan Yang; Jizhe Zhu; Huiyue Zhou; Lixia Ma; Mikiyas Amare Getu; Changying Chen; Tao Wang
Journal:  Asia Pac J Oncol Nurs       Date:  2022-07-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.